CAJ | 학술논문

胰岛素(insulin, INS)首次用于治疗糖尿病以来,随着对糖尿病病理和生理以及发病机制的深入研究,胰岛素得到了许多糖尿病患者的认可。随着重组DNA技术的发展,出现了一批新的长效胰岛素类似物：地特胰岛素(detemir)和德谷胰岛素(degludec)。它们在注射后均可以模拟人胰岛素的分泌方式,持续少量的释放,使餐前和餐后以及夜间的血糖保持稳定；但是随着各方面的深入研究,它们在分子结构、作用机制、生产工艺以及临床应用方面存在着许多不同之处。
이도소(insulin, INS)수차용우치료당뇨병이래,수착대당뇨병병리화생리이급발병궤제적심입연구,이도소득도료허다당뇨병환자적인가。수착중조DNA기술적발전,출현료일비신적장효이도소유사물：지특이도소(detemir)화덕곡이도소(degludec)。타문재주사후균가이모의인이도소적분비방식,지속소량적석방,사찬전화찬후이급야간적혈당보지은정；단시수착각방면적심입연구,타문재분자결구、작용궤제、생산공예이급림상응용방면존재착허다불동지처。
With the research of the pathophysiology and pathogenesis of diabetes, insulin (INS) had been widely used in the treatment of diabetes. And a number of new long-acting insulin analogues appeared with the development of recombination DNA technology, which could simulate normal basal secretion of insulin. Therefore, the blood sugar level could be kept stable between the intervals of meals or during the night. Insulin detemir and insulin degludec were two novel long-acting insulin analogues in the treatment of diabetes. This review presents the differences between Insulin detemir and insulin degludec in molecular structure, long-term mechanism of action, production process and clinical application.